IndiaCatalog.com
Login Signup
IndiaCatalog.com
Home Web Directory Classifieds Yellow Pages Global Directory City Guide News Photo Galleries
Login
Signup
  • Home
  • Global Web Directory
  • Drugs
Biotechnology
Diagnostic Substances
Drug Delivery
Drug Manufacturers - Major
Drug Manufacturers - Other
Drug Related Products
Drugs - Generic

Generics (UK) Limited

Generics (UK) Limited

Founded in 1981, Generics (UK) Limited is a subsidiary of Mylan, the world's third largest generic drug maker. Generics (UK) Limited covers the pharmaceutical business. The name pretty much says it all. Generics (UK) Limited is one of the UK's largest generic pharmaceutical manufacturers, offering a line of more than 350 products sold to pharmacy retailers, hospitals, and wholesale customers. The company makes generic equivalents of such drugs as acid reflux remedy Pepcid, antibiotic Cipro, and allergy treatment Zyrtec.

Bilcare, Inc.

Bilcare, Inc.

Bilcare, Inc., formerly ProClinical Pharmaceutical Services, is in favor of pharma. Bilcare, Inc. company, which also operates as Bilcare Global Clinical Services, is the American arm of parent company Bilcare Ltd. Its aim is to help pharmaceutical companies prepare for and conduct clinical trials. Bilcare's offerings include a wide range of analytical research, formulation development, manufacturing, and packaging and labeling of clinical supplies. Logistics services include the storage, distribution, reconciliation, and destruction of clinical trial supplies and investigational medicines. Its services encompass all levels of pharmaceutical drug trials.

Roche NimbleGen Inc.

Roche NimbleGen Inc.

Roche NimbleGen, founded in 1999, serves clients such as academic institutions, government laboratories, and pharmaceutical companies. It is a part of Roche Diagnostics. Roche NimbleGen displays agility in testing DNA. Formerly NimbleGen Systems, the company develops products and services for the analysis of genomes, which include the complete genetic material of an organism. The company produces high-density arrays of long oligo probes offering the deep high quality information necessary to study genomic variation base on ist proprietary Maskless Array Sythesis technology. By understanding the nature and function of genomes, scientists are able to improve a variety of medical and agricultural products.

A.P. Pharma, Inc.

A.P. Pharma, Inc.

A.P. Pharma, Inc. (A.P. Pharma) is a specialty pharmaceutical company focused on developing pharmaceutical products using its Biochronomer polymer-based drug delivery technology. The Company’s primary focus is on its lead product candidate, APF530, which completed a pivotal Phase III clinical trial for the prevention of chemotherapy-induced nausea and vomiting (CINV) during the year ended December 31, 2008. APF530 is designed to prevent CINV for at least five days and contains granisetron, a drug approved for the prevention of CINV. In addition to its lead drug candidate, A.P. Pharma has a pipeline of other product candidates that use its Biochronomer technology. One of these, APF112, incorporates the local anesthetic, mepivacaine. It is designed to provide up to 36 hours of post-surgical pain relief and to minimize the use of morphine-like drugs, or opiates, which are used in post-surgical pain management.

Inspire Pharmaceuticals, Inc.

Inspire Pharmaceuticals, Inc.

Inspire Pharmaceuticals was founded in 1993 and is based in Durham, North Carolina. Inspire Pharmaceuticals, Inc., a biopharmaceutical company, engages in researching, developing, and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. The company offers AzaSite, an azithromycin ophthalmic solution and topical anti-infective; Elestat, an epinastine HCl ophthalmic solution and topical antihistamine for the prevention of ocular itching associated with allergic conjunctivitis; and Restasis, a cyclosporine ophthalmic emulsion for the treatment of dry eye disease in adults and children in the United States. Its product candidates in clinical development include Prolacria, a diquafosol tetrasodium for the treatment of dry eye disease in phase III; denufosol tetrasodium, an inhaled product for the treatment of cystic fibrosis in phase III; AzaSite for the treatment of blepharitis, which is in phase II; and INS115644 and INS117548, which are in phase I clinical trial for the treatment of glaucoma or ocular hypertension. The company has a joint license agreement with Allergan, Inc. to develop and commercialize Prolacria; a license agreement with InSite Vision Incorporated to commercialize AzaSite, as well as other topical anti-infective products containing azithromycin used in the treatment of human ocular or ophthalmic indications primarily in the U.S. and Canada; and a development, license, and supply agreement with Santen Pharmaceutical Co., Ltd. for the development of diquafosol tetrasodium for the therapeutic treatment of ocular surface diseases in Asia.

Aaron Industries, Inc.

Aaron Industries, Inc.

Aaron Industries makes a lot of products you might be familiar with, but under different names. The pharmaceutical company makes approximately 75 different branded and private-label generic products, including alcohol, hydrogen peroxide, mouthwash, hair gel, and antacids and laxatives. It also produces cold medicine and cough suppressants and personal care products such as body sprays and lotions, as well as food-grade chemicals. Brands include Tussin, Pharmacist Preference, and Peptic Relief. Aaron Industries provides contract manufacturing and logistics services. The company operates two manufacturing facilities, one in California and one in South Carolina.

ARIAD Pharmaceuticals, Inc.

ARIAD Pharmaceuticals, Inc.

ARIAD Pharmaceuticals, Inc. company was founded in 1991 and is based in Cambridge, Massachusetts. ARIAD Pharmaceuticals, Inc. (ARIAD) is a biopharmaceutical company engaged in the discovery and development of medicines to treat cancers by regulating cell signaling with small molecules. The Company’s lead cancer product candidate, deforolimus, is an internally discovered, potent inhibitor of the protein mTOR, a master switch in cancer cells. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism and angiogenesis. Its second product candidate, AP24534, is a multi-targeted kinase inhibitor that has potential applications in cancer and is wholly owned by the Company. The company also focused drug discovery program centered on small-molecule therapies, molecularly targeted to cell-signaling pathways implicated in cancer. It also developed a portfolio of cell-signaling regulation technologies, its ARGENT technology, to control intracellular processes with small molecules.

Diversa Limited

Diversa Limited

Diversa Limited company has developed biosensor technology, drawing on work from the fields of biotechnology, nanotechnology, and electronics. Its primary technology is the Ion Channel Switch, a biosensing device. The Ion Channel Switch, or ICS, technology was developed using a membrane that acts as a switch, triggering an electrical current in the presence of particular molecules. Diversa plans to use the technology in point-of-care diagnostic products. The ICS was developed from research done by the Australian Membrane and Biotechnology Research Institute (AMBRI), the University of Sydney, and others.

Lectus Therapeutics Ltd.

Lectus Therapeutics Ltd.

Lectus Therapeutics Limited is a UK-based pharmaceutical company. Its mission is to build a development pipeline containing first-in-class ion channel therapeutics identified through the use of its proprietary proteomics technology for pain management and the treatment of urinary bladder disorders.Lectus, which began operations in the summer of 2003, exploits the power of its proprietary functional proteomics platform, LEPTICS® (Leveraged Enabling Proteomics Technology for Ion Channel Screening), and builds on its knowledge of ion channels and protein-protein interactions, to identify and develop next-generation ion channel modulators that offer desirable clinical profiles with commensurate economic advantages.

Forbes Medi-Tech Inc.

Forbes Medi-Tech Inc.

Forbes Medi-Tech has an answer for folks wanting to lower their cholesterol by changing their diet. The firm makes Reducol, a dietary supplement ingredient that reduces LDL, the "bad" cholesterol associated with increased risk of heart disease. It sells the ingredient to food and nutritionals companies that incorporate it into their products. Pharmavite uses Reducol in its Cholest-Off supplement, and foodmakers in Europe use it in items such as yogurt, milk, and bread. Until 2008 Forbes Medi-Tech also had a drug development operation, which was testing pharmaceutical candidates to treat high cholesterol and metabolic conditions; however, it has divested those operations to focus on its Reducol business.

Post a FREE Classified Advertisement

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.

Most Read News

IndiaCatalog News
BSE Smallcap index hits over 8-month low; 201 stocks fall to 52-week lows
IndiaCatalog News
Lodha signs MoU with Maharashtra to invest ₹1 trn in data centre park
IndiaCatalog News
'Roads kill, bridges kill, water kills': Rahul Gandhi on UP techie death
IndiaCatalog News
Ikea plans to double India investment to more than $2.20 billion over 5 yrs
IndiaCatalog News
Bihar CM asks to clear all pending land measurement applications by Jan 31

CORPORATE NEWS

Reliance Energy
Reliance Energy
Procter & Gamble India Ltd
Procter & Gamble India Ltd
Tata Motors
Tata Motors
LIC Housing Finance Ltd
LIC Housing Finance Ltd
BHEL
BHEL
Siemens Limited
Siemens Limited
Securities and Exchange Board of India ( SEBI )
Securities and Exchange Board of India ( SEBI )
Telecom Regulatory Authority of India
Telecom Regulatory Authority of India
IndiaCatalog.com

IndiaCatalog.com is a website brought to you by Portland Technologies to provide directory of Indian websites, News, City Guides and profiles of Indian Businesses. Portland Technologies also provides IT solutions for Small and Medium Businesses in India.


Products

India Web Directory

Global Web Directory

Yellow Pages

Photo Galleries

FREE India Classifieds


Useful links

About us

Advertise

Link to us

Submit a Site

Business Reviews


Contact

Plot #37, Ramnagar Gundu, Hyderabad - 500 044

service@indiacatalog.com

+91-40-23756949


© Copyright: IndiaCatalog.com